embolism - search results

If you're not happy with the results, please do another search

Rates of stroke and embolism lower with apixaban compared to rivaroxaban

In a large, population-based study of patients with atrial fibrillation (AF) and valvular heart disease, those receiving apixaban had a lower risk for ischaemic...

Patients undergoing robotic ablation found to have reduced incidence of silent cerebral embolism

Stereotaxis has announced the publication of the results of a prospective, multicentre study comparing the incidence of silent cerebral embolism (SCE) in atrial fibrillation...

Association found between left atrial appendage closure and readmission for thromboembolism

A collaborative study, has found that older patients with atrial fibrillation (AF) undergoing cardiac surgery accompanied with surgical left atrial appendage closure had a...
Cardiac Rhythm news for specialists

NICE recommends once-daily Lixiana (edoxaban) for preventing stroke and systemic embolism in non-valvular atrial...

The National Institute for Health and Care Excellence (NICE), the medicines cost-effectiveness body for England and Wales, has recommended a new treatment to help prevent stroke and systemic embolism in patients suffering from atrial fibrillation.
Cardiac Rhythm news for specialists

NICE recommends once-daily edoxaban for preventing stroke and systemic embolism in non-valvular atrial fibrillation...

NICE Final Appraisal Determination recommends that edoxaban is a cost-effective use of NHS resources.
Cardiac Rhythm news for specialists

Edoxaban approved for prevention of stroke and systemic embolism in non-valvular AF and treatment...

Daiichi Sankyo has announced that Swissmedic, the regulatory authority of Switzerland, has granted approval of Lixiana (edoxaban), an oral, once-daily selective factor Xa inhibitor, for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation and treatment of venous thromboembolism in deep vein thrombosis.
Cardiac Rhythm news for specialists

FDA approves Savaysa for reduction of stroke risk in non-valvular atrial fibrillation and for...

Savaysa (edoxaban) is an oral, once-daily selective factor Xa inhibitor, designed to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation
Cardiac Rhythm news for specialists

Stroke or systemic embolism uncommon in AF patients treated with apixaban within 30 days...

Results of a post-hoc subanalysis from the phase III ARISTOTLE trial have shown that stroke or systemic embolism and major bleeding were uncommon within 30 days in non-valvular atrial fibrillation patients who undertook a medical procedure.
Cardiac Rhythm news for specialists

Apixaban now available in the UK for the prevention of stroke and systemic embolism...

The oral anticoagulant is a new prescription only treatment option for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation and one or more risk factors such as: prior stroke or transient ischaemic attack; age 75 years or older; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).
Cardiac Rhythm news for specialists

European Commission approves apixaban for prevention of stroke and systemic embolism in non-valvular atrial...

The European approval for apixaban is supported by the pivotal phase 3 trials ARISTOTLE and AVERROES, which evaluated approximately 24,000 patients with non-valvular atrial fibrillation.
Cardiac Rhythm news for specialists

Apixaban receives CHMP positive opinion for the prevention of stroke and systemic embolism in...

The positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) was based on the pivotal ARISTOTLE and AVERROES studies, which evaluated apixaban in approximately 24,000 patients with non-valvular atrial fibrillation.
Cardiac Rhythm news for specialists

UK’s NICE releases final guidance on rivaroxaban for prevention of stroke and systemic embolism...

The guidance recommends rivaroxaban for people with non-valvular atrial fibrillation who have one or more risk factors such as congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, prior stroke or transient ischaemic attack.
Cardiac Rhythm news for specialists

Apixaban superior to aspirin in reducing stroke and systemic embolism in patients with atrial...

Bristol-Myers Squibb and Pfizer announced the full results of the AVERROES study of apixaban in The New England Journal of Medicine.
Cardiac Rhythm news for specialists

RE-LY: Dabigatran reduces incidence of stroke and systemic embolism

The anticoagulant dabigatran is more effective than warfarin in the prevention of stroke in patients with atrial fibrillation, according to results from the RE-LY study.
Cardiac Rhythm news for specialists

Chronic kidney disease increases risk of thromboembolism in AF

Study shows that knowing the level of kidney function and presence of proteinuria may improve decision making about the use of antithrombotic therapy.

Apixaban associated with lower risk of gastrointestinal bleeding in AF patients compared to other...

Use of apixaban was associated with a lower risk of gastrointestinal bleed and similar rates of ischaemic stroke or systemic embolism, intracranial haemorrhage and...

LeAAPS trial to explore benefit of left atrial appendage occlusion in cardiac surgery patients...

Researchers are to investigate the safety and efficacy of performing left atrial appendage occlusion in patients at high risk for atrial fibrillation (AF) who...

Puzzle Medical wins 2022 TCT Shark Tank innovation competition

Puzzle Medical Devices was announced as the winner of the Shark Tank innovation competition at the 2022 Transcatheter Cardiovascular Therapeutics meeting (TCT, 16–19 September,...

TVT 2022: DAPT after Watchman FLX LAAO is comparable to currently approved regimens

Dual antiplatelet therapy (DAPT) after left atrial appendage occlusion (LAAO) using the Watchman FLX (Boston Scientific) device was comparable in terms of rates of...

CRT 2022: SURPASS registry shows low rate of adverse events associated with Watchman FLX

Results from a new analysis assessing real-world outcomes with the Watchman FLX (Boston Scientific) left atrial appendage closure (LAAC) demonstrated a low rate of...
Kazunori Toyoda

Alternative timing method for direct oral anticoagulants following ischaemic stroke with atrial fibrillation deemed...

A new timely practice—known as the “1-2-3-4-day” rule—for the administration of direct oral anticoagulants (DOACs) in patients after acute ischaemic stroke or transient ischaemic...

TCT 2021: LAAC remains non-inferior to NOAC for cardiovascular events at long-term follow-up

Left atrial appendage occlusion (LAAC) remains non-inferior to non vitamin-K-antagonists (NOACs) for the prevention of major cardiovascular, neurological or bleeding events in patients with...

Continuous heart rhythm monitoring “does not prevent strokes in those at risk”

Continuous heart rhythm monitoring—with anticoagulation if atrial fibrillation (AF) is detected—does not prevent strokes in those at risk. That is the finding of the...

ESC 2021: Edoxaban shown to be noninferior to warfarin for adverse events after TAVI

Edoxaban is noninferior to warfarin and its analogues for adverse clinical events in patients with atrial fibrillation after transcatheter aortic valve implantation (TAVI), new...
Amplatzer Amulet

ESC 2021: Abbott’s Amulet occluder shows promise against Watchman device in AF treatment

Abbott has announced late-breaking data from the Amulet LAA Occluder IDE trial, a multicentre, head-to-head study comparing the company's Amplatzer Amulet left atrial appendage...

TVT 2021: Two-year PINNACLE FLX results report low rate of ischaemic stroke for Watchman...

Two-year results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the next-generation Watchman FLX (Boston Scientific) left atrial appendage closure...

ACC.21: Registry data show low rate of stroke at one year following LAAO with...

Transcatheter left atrial appendage occlusion (LAAO) with a Watchman (Boston Scientific) device was associated with a low rate of stroke at one year, even...

ACC.21: LAAO after heart surgery offers “new paradigm” for stroke prevention in AF patients

Patients with an elevated risk of stroke due to arrhythmia or atrial fibrillation (AF), were much less likely to suffer a stroke after undergoing...
emma svennberg atrial fibrillation screening

EHRA 2021: Efforts should be made to increase participation in atrial fibrillation screening

Further efforts should be made to increase participation in atrial fibrillation (AF) screening—particularly in elderly populations, where systematic screening for AF can help to...

DOACs show better safety and effectiveness versus warfarin in patients with valvular AF

Patients with valvular atrial fibrillation (AF) who were new users of direct oral anticoagulants (DOACs) were at lower risk for ischaemic stroke or systemic...

New recommendations issued on antithrombotic treatment of AF patients undergoing PCI

Updated recommendations on the optimal antithrombotic treatment of patients with atrial fibrillation (AF) receiving oral anticoagulants after undergoing percutaneous coronary intervention (PCI) have been...

ACC recommends against “triple therapy” in AF patients

The American College of Cardiology (ACC) has issued guidance recommending against triple antithrombotic therapy in patients with atrial fibrillation (AF), due to its increased...

Heavy alcohol consumption leads to higher stroke risk in AF patients

Fourteen drinks a week is linked with a higher risk of stroke and embolism in patients with atrial fibrillation (AF), according to research published...

AHA 2020: Active AF screening associated with significant improvement in clinical outcomes at three...

Three-year clinical outcomes of the mHealth Screening to Prevent Strokes—mSToPS—study evaluating silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using Zio, the...

AHA 2020: Rivaroxaban may be comparable to warfarin for bioprosthetic mitral valves, AF

The primary results from the RIVER Trial—Rivaroxaban for Valvular Heart disease and Atrial Fibrillation—show that rivaroxaban is comparable to warfarin for patients with bioprosthetic...

Append Medical completes transcatheter implant-free LAA occlusion procedures

Append Medical, developer of the Appligator implant-free left atrial appendage (LAA) occlusion device, today announced completion of its first pre-clinical chronic procedures. The procedures...

Boston Scientific initiates CHAMPION-AF trial of Watchman FLX

Boston Scientific has initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the Watchman FLX left atrial appendage closure (LAAC) device...

Study finds over 2,000 excess cardiovascular deaths in England and Wales during pandemic

Research has identified 2,085 excess deaths in England and Wales linked to cardiovascular disease during the peak of the COVID-19 pandemic. On average, that...

Low rates of bleeding and mortality reported in one-year results of ETNA-AF trial

Daiichi Sankyo Europe has announced the publication of one-year follow-up results from the ongoing ETNA-AF-Europe (Edoxaban Treatment in routiNe clinical prActice for patients with...

ACC publishes pathway on the management of bleeding in patients on oral anticoagulants

The American College of Cardiology has published an expert consensus decision pathway (ECDP) on the management of bleeding in patients being treated with direct...

PCR e-Course 2020: Roll-in trial finds high device success rate for Amplatzer Amulet occluder

Left atrial appendage occlusion (LAAO) using the Amplatzer Amulet (Abbott) device has a high implant success rate and a low procedural complication rate in...

FDA issues IDE for Impella ECP and EUA for Impella RP

Abiomed has received investigational device exemption (IDE) from the US Food and Drug Administration (FDA) for an early feasibility study with a first-in-human trial...

COVID-19: Anticoagulants may improve survival among hospitalised COVID patients

Corresponding author Valentin Fuster (Mount Sinai Heart, New York, USA) and colleagues report in the Journal of the American College of Cardiology that hospitalised...

Boston Scientific announces positive PINNACLE FLX study results

Boston Scientific has announced positive 12-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the next-generation WATCHMAN FLX Left...

Same-day discharge “feasible for majority of AF ablation patients”

Same-day discharge after atrial fibrillation (AF) ablation is feasible for the majority of patients when a standardised protocol is used, findings of a multicentre cohort study, published in the Journal of the American...

Portola Pharmaceuticals unveils data on Andexxa in patients with multiple types of Factor Xa...

Portola Pharmaceuticals announced new data that they say reinforces the value of Andexxa (coagulation factor Xa , inactivated-zhzo). The company statement outlines that the...

Algorithms can identify rate of OAC prescription for AF in emergency departments

Researchers have derived several algorithms to identify emergency department (ED) oral anticoagulant prescriptions for patients with atrial fibrillation (AF) in a large health dataset....
Vivek Reddy

Novel lattice tip catheter safe, feasible, and durable in RF ablation

Rapid high-current, temperature-controlled point-by-point pulmonary vein isolation (PVI) and linear ablation has been shown to be clinically feasible and safe in a first-in-human study...

Append Medical shares clinical proof-of-concept results for internal sealing of LAA

Append Medical, developer of the Appligator, a novel left atrial appendage (LAA) closure device to minimise stroke risk in atrial fibrillation (AF) patients, and...
European Trial Data

European trial data ‘reinforce’ safety profile and efficacy of Lixiana

Daiichi Sankyo Europe has announced outcomes from an observational study in mainly caucasian atrial fibrillation (AF) patients being treated with the anti-coagulation drug edoxaban...
BIBA MedTech LAA (quarterly) Monitor

BIBA Briefings: Longest and largest follow-up data for Watchman supports its role in stroke...

Data from the CAP and CAP2 registries—which contain the longest and largest follow-up of patients—add to previous evidence that left atrial appendage closure (LAAC)...
Abbott-mapping catheter

The Advisor HD Grid Mapping Catheter, Sensor Enabled, maps at high resolution and is...

Disclaimer: This advertorial is sponsored by Abbott The Advisor™ HD Grid Mapping Catheter, Sensor Enabled™ (SE), is a unique mapping catheter that, when used with...
Left atrial appendage closure results for preventing neurological events

ESC 2019: Left atrial appendage closure is non-inferior to NOACS for preventing neurological events

At the 2019 European Society of Cardiology (ESC) Congress (31 August–4 September, Paris, France), Pavel Osmancik (Charles University and University Hospital Kralovske Vinohrady, Prague,...

First-in-human study demonstrates safety and efficacy of QDOT MICRO ablation catheter

Data presented at Heart Rhythm 2019 (8–11 May, San Francisco, USA) and published in JACC: Clinical Electrophysiology indicates that the QDOT MICRO (Biosense Webster),...

Boston Scientific initiates trial comparing left atrial appendage closure to direct oral anticoagulants for...

According to a press release, Boston Scientific has initiated the OPTION trial to compare safety and effectiveness of the next-generation Watchman FLX left atrial...

Patients with atrial fibrillation who are frail or have cognitive impairment are less likely...

Malini Madhavan (Department of Cardiology, Mayo Clinic, Rochester, Minnesota, USA) and others reported the results of a study in American Heart Journal that found...
atrial fibrillation

New AHA treatment guidelines for use of blood thinners with atrial fibrillation

A newer type of blood-thinning medications, non-vitamin K oral anticoagulants (NOACs), is now recommended as the preferred alternative to warfarin for reducing the risk...

AHA 2018: Computerised-decision support has the potential to be a “powerful tool” for preventing...

Data presented at the 2018 American Heart Association (AHA) scientific session scientific sessions (10–12 November, Chicago, USA) indicate that the use of alert-based computerised-decision...

Analysis of the BRUISE CONTROL 1 and 2 trials shows no difference in clinically...

By Hannah Woolley In a multivariate analysis including both BRUISE CONTROL 1 and BRUISE CONTROL 2 patients and adjusted for antiplatelet use, there was no...

 Octreotide enables left atrial appendage closure in AF patients with GI bleeding

Octreotide therapy has the potential to offer atrial fibrillation (AF) patients with arteriovenous malformations (AVM) related gastrointestinal (GI) bleeding another treatment option. It is...

RHYTHM study published revealing link between total AF burden and stroke risk

iRhythm Technologies has announced results of a study which utilised Zio by iRhythm, an extended continuous cardiac monitoring system, to provide a comprehensive picture...

New real-world study finds long-term rivaroxaban use resulted in fewer strokes and systemic emboli...

Two-year results show rivaroxaban was associated with reduced stroke and systemic embolism versus warfarin, without altering risk of major bleeding. The study evaluated efficacy...

How much should we screen?

At the AF Symposium (Orlando, USA) John Camm, St George’s University of London and Imperial College, London, UK, looked at the current status of...

Factor XI inhibitors: a new class of anticoagulants that may reduce the risk of...

More patients than ever before are being given NOACs due to their relative stability and safety, but the risk of gastrointestinal bleeding with NOACs...

Brain MRI scans can inform the choice between OACs and LAA closure for non-valvular...

M Edip Gurol is a stroke neurologist with particular expertise in the care of patients at high risk for ischaemic (blockage type) strokes and...

Interim results from ongoing ANNEXA-4 study of Factor Xa inhibitor reversal agent announced

Interim data from 228 patients (of which 132 were adjudicated for efficacy) showed that AndexXa rapidly and significantly reversed anti-Factor Xa activity (the anticoagulant...

Short-term DAPT is feasible for patients undergoing percutaneous LAA closure

Felix Weise (Cardioangiologisches Centrum Bethanien, Frankfurt, Germany) and others report in EuroIntervention that a strategy of six weeks’ duration of dual antiplatelet therapy (DAPT)...

Warfarin linked to lower rate of cancer, particularly for atrial fibrillation patients

A recent study by Gry Haaland (University of Bergen, Bergen, Norway) et al published in the Journal of the American Association of Medicine (JAMA):...

FDA mini-sentinel assessment confirms safety and effectiveness of Xarelto (rivaroxaban) amidst lawsuit

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced findings from the US Food and Drug Administration's (FDA) mini-sentinel assessment, confirming the positive...

Use of apixaban prior to cardioversion reduces risk of stroke

According to the results of the EMANATE trial, patients with atrial fibrillation (AF) who receive apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) before undergoing elective cardioversion of...

EMA issues positive opinion for updated dabigatran summary of characteristics

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for an update to...

Three studies support efficacy of PFO closure for reducing risk of recurrent stoke

The results of CLOSE, Gore Reduce and the extended follow-up of RESPECT—all published in The New England Journal of Medicine—indicate that percutaneous closure of...

ESC 2017: Apixaban lowers risk of stroke in atrial fibrillation patients undergoing cardioversion

Data from the EMANATE trial, which was presented at a Hot Line session of the European Society of Cardiology (ESC) congress (26–30 August, Barcelona,...

Repeat ablation with contact force sensing “does not necessarily guarantee a successful outcome” in...

Preliminary results from the ABLATOR observational registry have shown similar success rates (around 58%) in first time ablation and repeat ablation for persistent atrial...

HRS 2017: True incidence of atrial fibrillation is underestimated

A substantial number of patients at risk for atrial fibrillation (AF) may remain undetected using conventional monitoring techniques, a late-breaking clinical trial session at...

Surgical left atrial appendage occlusion reduces thromboembolic stroke and mortality in older AF patients

Surgical left atrial appendage occlusion (LAAO) is associated with a reduction of thromboembolism and all-cause mortality among older atrial fibrillation (AF) patients undergoing cardiac...

ACC 2017: Uninterrupted dabigatran performs better than warfarin in atrial fibrillation ablation

Results from the RE-CIRCUIT study have shown that uninterrupted dabigatran (Pradaxa, Boehringer Ingelheim), was associated with fewer bleeding complications than uninterrupted warfarin before, during...

AF Symposium 2017: Use of intracardiac echocardiography is a “viable option” for Amplatzer Amulet...

Intracardiac echocardiograpy (ICE) facilitates a high success implant rate of the Amplatzer Amulet left atrial appendage (LAA) occluder (St Jude Medical/Abbott) as well as...

Case strengthens for opportunistic atrial fibrillation screening

By Angela Gonzalez In the quest to reduce the number of atrial fibrillation (AF) related strokes, which account for a third of all ischaemic strokes,...
Cardiac Rhythm news for specialists

Health Canada approves edoxaban for two indications

Health Canada has approved edoxaban (Lixiana, Servier Canada) for the prevention of stroke and for systemic embolic events in patients with non-valvular atrial fibrillation,...

Amulet study shows high implant success rates with Amplatzer Amulet LAA occluder

A study presented at the last late-breaking trial session of the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October-2 November, Washington, DC, USA) indicates...

ESC 2016: “User-friendly” risk score may help to better identify atrial fibrillation patients at...

A new risk score, based on data from GARFIELD-AF (Global anticoagulation registry in the field), may be superior to the CHA2DS2-VASc score at predicting...

Daiichi Sankyo PREFER in AF registry suggests increased stroke risk among diabetic atrial fibrillation...

Daiichi Sankyo has announced data from new sub-analyses of the Prevention of thromboembolic events—European Registry in Atrial Fibrillation (PREFER in AF) patient registry, which...

Results of phase 3b ENSURE-AF study investigating edoxaban in AF patients undergoing cardioversion to...

Daiichi Sankyo has announced it will present the first results from ENSURE-AF, the largest prospective randomised clinical trial to date evaluating a non-vitamin K...

Thrombosis Research Institute to announce new real-world GARFIELD-AF registry insights in atrial fibrillation at...

New analyses from the Global Anticoagulant Registry in the Field-Atrial Fibrillation (GARFIELD-AF) will be presented at the European Society of Cardiology (ESC) Congress (27‒31...

American Academy of Neurology advises not to routinely offer percutaneous PFO closure outside of...

  A practice advisory update from the American Academy of Neurology (AAN) suggests that percutaneous patent foramen ovale (PFO) closure to patients with cryptogenic ischaemic...

Boston Scientific is suspending sales of Watchman FLX in Europe

According to a Reuters news report, Boston Scientific is temporarily suspending sales of Watchman FLX—the next-generation of its left atrial appendage closure device, Watchman....

Implantation of multiple leadless pacemakers is feasible without impacting cardiac function

An animal study from China has indicated that it is feasible to implant two leadless pacemakers in the right ventricle of the same heart without impacting cardiac function at six months.

German public health body grant once-daily edoxaban indication for prevention of stroke in non-valvular...

The German Federal Joint Committee (Gemeinsamer Bundesausschuss-G-BA) has granted Daiichi Sankyo's edoxaban (Lixiana) an indication of a minor additional benefit.

Biosense Webster acquires Coherex Medical

This acquisition adds the Coherex WaveCrest left atrial appendage (LAA) occlusion system to BioSense's portfolio.

Idarucizumab gets accelerated FDA approval for use in patients in need of emergency reversal...

Idarucizumab (Praxbind) is the first reversal agent approved specifically for dabigatran and works by binding to the drug compound to neutralise its effect.
Cardiac Rhythm news for specialists

First patient enrolled in study of Eliquis (apixaban) in NVAF patients with recent acute...

This two-by-two factorial, randomised controlled trial will evaluate the safety of Eliquis versus warfarin or other vitamin K antagonists (VKA) in patients with NVAF and a recent acute coronary syndrome or undergoing PCI.

New trial to explore oral anticoagulation benefit in patients with atrial high rate episodes

The Atrial Fibrillation Network (AFNET) association and the European Society of Cardiology (ESC) are initiating a new trial (NOAH – AFNET 6) investigating whether...

First ESC recommendations for arrhythmias and chronic kidney disease published

The first ESC recommendations for patients with cardiac arrhythmias and chronic kidney disease (CKD) were presented at EHRA EUROPACE - CARDIOSTIM 2015 (21-24 June, Milan, Italy) and published in EP Europace.
Cardiac Rhythm news for specialists

Edoxaban approved in the European Union

Edoxaban (Lixiana, Daiichi Sankyo) is an oral, once-daily selective factor Xa-inhibitor for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors.
Cardiac Rhythm news for specialists

One-year outcomes on stroke prevention in patients with newly-diagnosed atrial fibrillation to be presented...

Real-life data on stroke prevention from 17,200 patients will provide information on how patient risk profiles and quality of vitamin K antagonist control are associated with increased mortality and stroke in patients with newly diagnosed atrial fibrillation.

Benefit of anticoagulation in AF patients with a low risk of stroke questioned

The results from a retrospective study, based on a large dataset (over 140,000 patients), have cast doubt on the benefit of routine oral anticoagulants for patients with atrial fibrillation and low risk of stroke.
dabigatran

First patient enrolled in dabigatran study comparing anticoagulation strategies during atrial fibrillation ablation

The study assesses the safety and efficacy of uninterrupted anticoagulation with dabigatran etexilate (Pradaxa) during ablation procedures compared to warfarin. Results from the study are expected during 2016.

Many atrial fibrillation patients at high risk of stroke fail to receive guideline-recommended oral...

First phase II data demonstrating anticoagulant prescribing patterns in North America now available from GLORIA-AF Registry programme.
Cardiac Rhythm news for specialists

Atrial fibrillation patients on digoxin face increased risk of death

Analysis of 19 studies finds atrial fibrillation patients taking digoxin are 27% more likely to die than those who do not.

Real-world multicentre study shows positive outcomes with left atrial appendage occlusion for stroke prevention...

The largest study using the Amplatzer Cardiac Plug (St Jude Medical) for left atrial appendage occlusion has shown a high procedural success rate and favourable outcomes for prevention of atrial fibrillation-related thromboembolism.

Bridging during anticoagulation interruption associated with higher bleeding risk in AF patients

A subanalysis from the ORBIT-AF registry has found that atrial fibrillation patients who receive bridging anticoagulation therapy during anticoagulation interruption are at higher risk of bleeding and adverse events following interruption than patients who do not receive bridging anticoagulation.
rivaroxaban

Bayer collaborates on phase III study to evaluate Xarelto in embolic stroke patients

In addition, Xarelto (rivaroxaban) label now includes guidance for use in patients with atrial fibrillation undergoing cardioversion.

Watchman presents possible alternative to warfarin for stroke prevention in patients with atrial fibrillation

Study examines the long-term efficacy and safety of Boston Scientific's Watchman device to achieve left atrial appendage closure in patients with atrial fibrillation.
Cardiac Rhythm news for specialists

Dabigatran associated with higher incidence of major bleeding than warfarin

A study of Medicare beneficiaries suggests that dabigatran (Pradaxa, Boehringer Ingelheim) should be prescribed with caution, especially among high risk patients, as it may be associated with a higher incidence of major bleeding and a higher risk of gastrointestinal bleeding, despite a lower risk of intracranial haemorrhage than warfarin, according to a study published online in JAMA Internal Medicine.
Cardiac Rhythm news for specialists

FDA makes recommendation on Daiichi Sankyo’s Savaysa

Daiichi Sankyo has announced that the FDA has recommended approval of once-daily Savaysa (edoxaban) 60mg dosing regimen.

FDA’s Advisory Committee Panel votes in favour of Watchman device

Members of the US Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee have voted in favour of the Watchman left atrial appendage closure (LAAC) device (Boston Scientific), by a close vote of 6 to 5 (with 1 abstention) concluding that the potential benefits of Watchman outweigh the potential risks. The Panel also voted unanimously in favour of the device safety; however, its effectiveness saw unfavourable voting.

Rivaroxaban may be a safe alternative to standard of care in AF patients undergoing...

Results from the X-VERT trial have shown that rivaroxaban is a safe and effective alternative to Vitamin K antagonist (VKA) therapy in patients with atrial fibrillation who are undergoing elective cardioversion.

Antithrombotic therapy after left atrial appendage closure

Uncertainty exists about the optimal post-interventional antithrombotic drug regimen as well as treatment duration after left atrial appendage closure; Boris Schmidt and KR Julian...
Cardiac Rhythm news for specialists

SMART-AF trial shows AF ablation with contact force sensing catheter is safe and effective

Results from the SMART-AF trial, recently published in the Journal of the American College of Cardiology, have shown that the ThermoCool SmartTouch contact force-sensing catheter is safe and effective for the treatment of drug-refractory symptomatic paroxysmal atrial fibrillation.
Cardiac Rhythm news for specialists

Joint consensus on antithrombotic use in AF patients with acute coronary syndrome published

A new European joint consensus document on the use of antithrombotic drugs in patients with atrial fibrillation presenting with an acute coronary syndrome and undergoing percutaneous coronary intervention has been published in the European Heart Journal.
Cardiac Rhythm news for specialists

Bristol-Myers Squibb and Pfizer to present new Eliquis (apixaban) data at ESC

Bristol-Myers Squibb Company and Pfizer have announced that they will present 14 abstracts (oral and poster presentations) at the ESC Congress 2014, 30 August to 4 September in Barcelona, Spain.
Cardiac Rhythm news for specialists

New study of Pradaxa to explore anticoagulation in ablation of AF patients

The RE-CIRCUIT study will investigate the safety and efficacy of uninterrupted anticoagulant treatment with Pradaxa in patients with atrial fibrillation who undergo ablation. Results of the study are expected in 2016.
Cardiac Rhythm news for specialists

NICE no longer recommends aspirin alone for reducing risk of stroke in AF patients

Updated National Institute for Health and Care Excellence (NICE) guidelines no longer recommend aspirin use alone, solely to reduce the risk of stroke in patients with atrial fibrillation (AF).

Greater surveillance necessary to improve significant public health burden of sudden cardiac death

New research in the USA finds that the societal burden of sudden cardiac death is high relative to other major causes of death.
Cardiac Rhythm news for specialists

Eliquis (apixaban) recommended for prevention of stroke

Eliquis (apixaban) has been recommended for continued use for prevention of stroke / systemic embolism in patients with non valvular atrial fibrillation while undergoing cardioversion by European Medicines Agency's Committee for Medicinal Products for Human Use.
Cardiac Rhythm news for specialists

Daiichi Sankyo extends the PREFER in AF patient registry

The extension of the registry will include a specific focus on the use of novel oral anticoagulant therapy including prescribing patterns, providing new insight into the long-term management of patients with atrial fibrillation.
Cardiac Rhythm news for specialists

Daiichi Sankyo initiates phase 3 ENSURE-AF study

The first patient has been enrolled in the largest planned phase 3 study evaluating novel oral anticoagulant edoxaban in non-valvular atrial fibrillation patients undergoing electrical cardioversion.
Cardiac Rhythm news for specialists

Edoxaban evaluated in two subgroup analyses of East Asian patients from the largest comparative...

Subgroup analyses of East Asian populations from two phase 3 studies, ENGAGE AF-TIMI 48 and Hokusai-VTE, showed consistent results compared to the global study populations from these trials.
Cardiac Rhythm news for specialists

Apixaban is cost-effective compared with standard of care for stroke prevention in atrial fibrillation

Based on randomised trial data and from the UK payer perspective, apixaban is a cost-effective alternative to warfarin and aspirin for stroke prevention in atrial fibrillation patients.
Cardiac Rhythm news for specialists

Pradaxa (dabigatran etexilate) now approved in more than 100 countries

More than 100 countries have now approved Boehringer Ingelheim's Pradaxa for the prevention of stroke and systemic embolism for adult patients with non-valvular atrial fibrillation.
Cardiac Rhythm news for specialists

Subanalysis of phase 3 ARISTOTLE shows apixaban reduced risk of stroke vs. warfarin in...

The subanalysis shows that apixaban was more effective than warfarin in reducing the risk of stroke or systemic embolism, was associated with less major bleeding, less total bleeding and less intracranial haemorrhage, regardless of age and in reducing all-cause mortality across age groups.

Insertable loop recorders offer “the best opportunity” to diagnose unexplained syncope and abnormal heart...

Nick Linker, Middlesbrough, UK, recently implanted, for the first time in the UK, the smallest version of an insertable loop recorder. He spoke to Cardiac Rhythm News on the role and advantages of implantable loop recorders in the diagnosis of syncope and cardiac arrhythmias, the main features of this new device and its cost-effectiveness.

Anne Curtis

Anne Curtis is past president (2005-2006) of the Heart Rhythm Society. She has been involved in various clinical trials in electrophysiology including her most recent trial, BLOCK HF, and is currently a member of different editorial boards in the field. She spoke to Cardiac Rhythm News about her career achievements, memorable cases and the major challenges executing a trial.
Cardiac Rhythm news for specialists

New drug application for edoxaban submitted in Japan

Daiichi Sankyo is seeking approval in Japan for edoxaban in new indications for non-valvular atrial fibrillation and symptomatic venous thromboembolism.
Cardiac Rhythm news for specialists

Meta-analysis shows all four novel oral anticoagulants perform better than warfarin

A first-of-its-kind meta-analysis comparing four new oral anticoagulants with warfarin has found they perform better than warfarin reducing stroke, intracranial haemorrhage and mortality in atrial fibrillation patients. The study was published ahead-of-print in The Lancet.

Does the anatomy of left atrial appendage correlate with the risk of stroke?

Luigi Di Biase writes for Cardiac Rhythm News on the results of a study that identified four different left atrial appendage morphologies and its relationship with the risk of stroke in atrial fibrillation patients. "These results could have a relevant impact on the oral anticoagulation management and occlusion device management of atrial fibrillation patients with an intermediate risk for stroke," writes Di Biase.
Cardiac Rhythm news for specialists

Edoxaban not inferior to warfarin in stroke prevention for atrial fibrillation patients

Results from the ENGAGE AF-TIMI 48 clinical trial have found that the investigational, oral, once daily direct factor Xa-inhibitor edoxaban (Lixiana, Daiichi-Sankyo) met the primary efficacy endpoint of non-inferiority compared to warfarin for the prevention of stroke or systemic embolic events in patients with non-valvular atrial fibrillation.

Clinical strategies for selecting oral anticoagulants in atrial fibrillation patients

With the advent of new oral anticoagulants, there are many questions towards selection of the most appropriate treatment for patients with atrial fibrillation. Sean D Pokorney (Durham, USA) writes for Cardiac Rhythm News about the different clinical strategies to take into consideration based on the results of landmark clinical trials of novel oral anticoagulants.

Antonio Raviele

Antonio Raviele (Venice, Italy), cofounder of the VeniceArrhythmias congress, implanted the first intravenous defibrillator lead in Italy. He spoke to Cardiac Rhythm News about this experience, his current research, his projects dedicated to enhance awareness on cardiac arrhythmias and the highlights of VeniceArrhythmias 2013
Cardiac Rhythm news for specialists

WaveCrest LAA Occlusion System is CE-marked

The WaveCrest is an implantable device that seals off the left atrial appendage (LAA) opening so clots cannot escape into the blood stream and cause a stroke.
Cardiac Rhythm news for specialists

Dabigatran shows sustained benefit in difficult to treat patients with atrial fibrillation and symptomatic...

Results from a new sub-analysis of the RE-LY trial support consistent benefit of dabigatran (Pradaxa, Boehringer Ingelheim) over warfarin in difficult-to-treat patients with non-valvular atrial fibrillation and previous symptomatic heart failure.
Cardiac Rhythm news for specialists

RELY-ABLE results support long-term safety of dabigatran in non-valvular atrial fibrillation patients

Results from the RELY-ABLE trial, a long-term extension of the pivotal RE-LY study of dabigatran (Pradaxa / Boehringer Ingelheim) in patients with non-valvular atrial fibrillation, have provided additional information showing long-term safety of dabigatran.

Effectiveness of left atrial appendage exclusion, ligation and occlusion in reducing stroke risk in...

Andre d'Avila and Arash Aryana write on three different left atrial appendage strategies aimed to reduce stroke risk in atrial fibrillation patients. d'Avila presented this analysis at Heart Rhythm (Denver, USA, 8-5 May 2013).
Cardiac Rhythm news for specialists

IMPACT study of Biotronik Home Monitoring completes enrolment

The IMPACT study aims to investigate whether the use of Biotronik Home Monitoring in conjunction with anticoagulation can reduce the risks of stroke, systemic embolism and major bleeding in cardiac device patients.
Cardiac Rhythm news for specialists

Continued warfarin better than heparin bridging during device implantation

A randomised trial (BRUISE CONTROL) has shown that performing device implantation surgery without interruption of warfarin in patients with an annual risk of stroke equal to or over 5% was associated with a significant reduction in device pocket haematoma. Data was presented at the Heart Rhythm Society (HRS) meeting in Denver, USA.
Cardiac Rhythm news for specialists

UK’s NICE supports improved commissioning for anticoagulation therapy for adults

On 14 May, UK's National Institute for Health and Care Excellence (NICE) issued updated support for commissioners to help them work with clinicians and managers to commission high-quality, evidence-based anticoagulation therapy for adults across England.
Cardiac Rhythm news for specialists

PREVAIL shows Watchman device is safe; efficacy is still under discussion

Preliminary results of the PREVAIL trial have demonstrated the Watchman device (Boston Scientific / Atritech) is a safe alternative to oral anticoagulation therapy for stroke prevention in non-valvular atrial fibrillation patients. However, there are now questions towards Watchman's efficacy.
Cardiac Rhythm news for specialists

PREVAIL preliminary results of Watchman device to be revealed at ACC 2013

Boston Scientific will present, for the first time, preliminary results of all three co-primary endpoints of the Watchman device at the American College of Cardiology 2013 Annual Scientific Sessions.
Cardiac Rhythm news for specialists

UK’s NICE publishes final guidance recommending apixaban to prevent stroke in non-valvular atrial fibrillation...

On 27 February, the UK's National Institute for Health and Clinical Excellence (NICE) released final guidance recommending apixaban (Eliquis, Bristol-Myers Squibb and Pfizer) as an option for the prevention of stroke and systemic embolism in some people with non-valvular atrial fibrillation.
Cardiac Rhythm news for specialists

Massachusetts General Hospital launches the Institute for Heart, Vascular and Stroke Care

According to a Massachussetts General Hospital press release this is one of the only institutes in the world to integrate cardiovascular and cerebrovascular care.
Cardiac Rhythm news for specialists

The Scottish Medicines Consortium accepts apixaban for prevention of Stroke in non-valvular atrial fibrillation...

The Scottish Medicines Consortium has accepted the novel oral anticoagulant apixaban (Eliquis, Bristol-Myers Squibb / Pfizer) for use within NHS Scotland for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors.
Cardiac Rhythm news for specialists

Long-term results of PROTECT AF confirm left atrial appendage closure is non-inferior to warfarin

Vivek Y Reddy, Mount Sinai School of Medicine, New York, USA, and others recently reported the updated results ahead of print in Circulation.

Gregory YH Lip

Gregory YH Lip, Birmingham, UK, talked to Cardiac Rhythm News about the highlights of his career, including his mother as his biggest influence, and the recent update to the European Society of Cardiology (ESC) guidelines for the management of atrial fibrillation.

Are patients with atrial fibrillation at increased risk of developing dementia?

Pasquale Santangeli, Texas Cardiac Arrhythmia Institute, St David's Medical Centre, Austin, USA, spoke to Cardiac Rhythm News about the link between atrial fibrillation and dementia.
Cardiac Rhythm news for specialists

NICE recommends apixaban for some people with non-valvular atrial fibrillation

On 23 January, the UK's National Institute for Health and Clinical Excellence (NICE) issued a final draft guidance recommending apixaban (Eliquis, Bristol-Myers Squibb and Pfizer), in accordance with its licensed indications, for the prevention of stroke and systemic embolism in some people with non-valvular atrial fibrillation.
Cardiac Rhythm news for specialists

FDA approves apixaban to reduce the risk of stroke in AF patients

On 28 December 2012, the FDA approved the anticlotting drug apixaban (Eliquis, Bristol-Myers Squibb), an oral tablet used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Cardiac Rhythm news for specialists

Dabigatran may be associated with better patient outcomes after a major bleeding event compared...

Findings from the RE-LY trial and four other phase III trials report outcomes after a major bleed on dabigatran, despite the lack of a specific reversal agent, may be better than after a warfarin-associated bleed.
Cardiac Rhythm news for specialists

Dabigatran demonstrates sustained positive outcomes for over four years, RELY-ABLE study shows

New data from the RELY-ABLE study have provided additional support to the safety profile and efficacy of dabigatran etexilate (Pradaxa, Boehringer Ingelheim) for stroke prevention in patients with non-valvular atrial fibrillation.
Cardiac Rhythm news for specialists

Catheter ablation can be performed safely while a patient is on uninterrupted warfarin

Stephen Page and Richard Schilling, St Bartholomew's Hospital, UK, explain why catheter ablation can be performed safely in most patients with uninterrupted warfarin.
Cardiac Rhythm news for specialists

FDA acknowledges receipt of resubmission of apixaban’s new drug application

The new drug application for apixaban (Eliquis / Bristol-Myers Squibb and Pfizer) is intended to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

Anne Gillis

Anne Gillis, current president of the Heart Rhythm Society (HRS), talked to Cardiac Rhythm News about her career achievements, her plans for the HRS and the role of the society to encourage women into electrophysiology.
Cardiac Rhythm news for specialists

Should female gender be included in risk scores for stroke?

Female gender is only a significant risk for stroke in patients with atrial fibrillation among those aged ≥75 years-indicating its inclusion in risk scores for stroke may not be required, according to study presented at the ESC annual meeting.
Cardiac Rhythm news for specialists

Female gender increases stroke risk in older AF patients by 20%

According to a study presented at the annual meeting of the European Society of Cardiology (ESC), 25-29 August, Munich, Germany, being female increases the risk of stroke in patients with atrial fibrillation who are >75 years by 20%
Cardiac Rhythm news for specialists

Watchman Left Atrial Appendage Closure Device receives CE mark approval for expanded use

The Watchman device (Boston Scientific) is indicated to be used in patients with atrial fibrillation and a contraindication to warfarin and the newer oral anticoagulants.
Cardiac Rhythm news for specialists

Rivaroxaban to be explored in two new studies

X-VeRT and VENTURE-AF will evaluate rivaroxaban (Xarelto, Bayer HealthCare) in patients with non-valvular atrial fibrillation undergoing cardioversion or ablation therapy.
Cardiac Rhythm news for specialists

Indirect comparison of new anticoagulants provides insight into how the drugs compare

Gregory Lip and colleagues have made an indirect comparison of the new anticoagulants. They have found "no profound significant differences" in efficacy between apixaban (Eliquis, Pfizer and Bristol-Myers Squibb) and both does of dabigatran (Pradaxa, Boehringer Ingelheim) and Rivaroxaban (Xarelto, Bayer).
Cardiac Rhythm news for specialists

Patient enrolment in PREVAIL study for Watchman device completed

The PREVAIL study is designed to gain FDA approval for the Watchman Left Atrial Appendage (LAA) Closure device (Boston Scientific).
Cardiac Rhythm news for specialists

FDA responds letter for apixaban’s new drug application

Bristol-Myers Squibb and Pfizer announced that the FDA has issued a complete response letter regarding the new drug application for apixaban (Eliquis) for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

European perspective on the RCPE guidelines

John Camm and Karl-Heinz Kuck, on behalf of the European Heart Rhythm Association (EHRA), review the recent consensus document from the Royal College of Physicians of Edinburgh (RCPE) on the management of atrial fibrillation.
Cardiac Rhythm news for specialists

Watchman device shows 75% reduction in stroke risk in patients with atrial fibrillation not...

Vivek Reddy, New York, USA, presented results from the ASA Plavix (ASAP) study of the Watchman Left Atrial Appendage Closure (LAAC) device (Boston Scientific) during a late-breaking session at the Heart Rhythm Society's 33rd Annual Scientific Sessions in Boston, USA.
Cardiac Rhythm news for specialists

Stroke risk high when anti-clotting drugs stopped

Some patients with certain types of atrial fibrillation who are taken off anti-clotting medication face a high risk of stroke or blood clotting within a month, according to new research presented at the American Heart Association's Emerging Science Series webinar.
Cardiac Rhythm news for specialists

UK’s NICE recommends second new anticoagulant for atrial fibrillation

Following its recent recommendation for dabigatran (Pradaxa, Boehringer Ingelheim), the UK's National Institute for Health and Clinical Excellence (NICE) now recommends rivaroxaban (Xarelto, Bayer) as an option for preventing stroke and systemtic embolism in patients with non-valvular atrial fibrillation.
Cardiac Rhythm news for specialists

FDA extends action date for apixaban’s new drug application by three months

Bristol-Myers Squibb and Pfizer have announced that the US Food and Drug Administration (FDA) has extended the action date by three months for the new drug application for apixaban (Eliquis) for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Cardiac Rhythm news for specialists

Scottish Medicines Consortium accepts rivaroxaban for NHS use in two new indications in Scotland

The anticoagulant rivaroxaban (Bayer HealthCare, Xarelto) has been accepted for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation who have one or more risk factors and for the treatment of deep vein thrombosis (DVT) and prevention of recurrent DVT and pulmonary embolism, following an acute DVT in adults.
Cardiac Rhythm news for specialists

Subclinical atrial tachyarrhythmias, without clinical atrial fibrillation, increase the risk of stroke

A new study, published in the New England Journal of Medicine, has added weight to the view that subclinical atrial fibrillation is a possible cause of cryptogenic stroke after finding that 13% of strokes and systemic embolisms in the study population were associated with subclinical atrial tachyarrhythmias.
Cardiac Rhythm news for specialists

Data from ASSERT implantable device monitoring study published in New England Journal of Medicine

Study illustrates the effectiveness of detecting patients with higher risk of stroke using implantable device monitoring.
Cardiac Rhythm news for specialists

Trial reviews and live case presentations at Boston AF

The first day of Boston AF (12 January 2012, Boston, Massachusetts, USA) was a mixture of best paper reviews and live case presentations.
Cardiac Rhythm news for specialists

Experts unveil tools to improve atrial fibrillation care

Four interventions to enhance the care and treatment of individuals with atrial fibrillation were presented on 10 January 2011 at a press briefing hosted by The American College of Physicians Foundation's initiative on atrial fibrillation and stroke prevention.
Cardiac Rhythm news for specialists

Dabigatran associated with increased risk of acute coronary events

The anticoagulant dabigatran (Boehringer Ingelheim's Pradaxa) is associated with an increased risk of myocardial infarction or acute coronary syndrome in a broad spectrum of patients when tested against some other medicines, according to a study published online by the Archives of Internal Medicine.
Cardiac Rhythm news for specialists

NICE needs more evidence on rivaroxaban for prevention of stroke in atrial fibrillation patients

In preliminary recommendations published on 9 January, NICE is asking Bayer HealthCare for more information on its product rivaroxaban (Xarelto), for the prevention of stroke and systemic embolism in people with atrial fibrillation.
Cardiac Rhythm news for specialists

FDA adds new warnings to dronedarone

Dronedarone (Multaq, Sanofi Aventis) should not be prescribed to patients with atrial fibrillation who cannot or will not be converted into normal sinus rhythm, FDA advises.
Cardiac Rhythm news for specialists

Rivaroxaban approved in the UK for two new indications

Rivaroxaban (Xarelto, Bayer Healthcare) has been approved in the UK for the prevention of non-valvular AF-related stroke and systemic embolism and treatment of deep vein thrombosis (DVT) and prevention of recurrent DVT and pulmonary embolism following an acute DVT in adults.

The future of remote monitoring

Stefan Sack, Munich, Germany speaks to Cardiac Rhythm News about what current data for remote monitoring shows and what studies on remote monitoring are currently investigating.
Cardiac Rhythm news for specialists

More work needed to reduce strokes due to atrial fibrillation in UK

A study published in BMJ Open has found that although the number of strokes has fallen in the UK, more needs to be done to reduce the risk of stroke in patients with atrial fibrillation. Additionally, it seems that while the use of anticoagulants does not increase with increasing CHADS2 (congestive heart failure, hypertension, age, diabetes, stroke) score in patients with atrial fibrillation, the use of antiplatelets does increase
Cardiac Rhythm news for specialists

Surgical ablation is more effective but has more procedure-related adverse events than catheter ablation

A trial, simultaneously published online in Circulation and presented at the annual scientific sessions of the American Heart Association (AHA; 12-16 November, Orlando, Florida) has found that minimally invasive surgical ablation is more effective than catheter ablation but is also associated with more procedure-related adverse events
Cardiac Rhythm news for specialists

Watchman device implanted in first patients in Latin America

The Watchman device (Boston Scientific) is designed for use in patients with atrial fibrillation who are at risk for stroke and are eligible for long-term oral anticoagulation therapy such as warfarin. The device is designed to close the left atrial appendage therefore could be used as an alternative to long-term anticoagulation therapy.
Cardiac Rhythm news for specialists

New RE-LY sub-analyses demonstrate safety and efficacy of Pradaxa in patients with heart failure...

Pradaxa (dabigatran etexilate) 150mg bid reduced the risk of stroke in atrial fibrillation patients with symptomatic heart failure and non-valvular atrial fibrillation compared to well-controlled warfarin.
Cardiac Rhythm news for specialists

NICE recommends dabigatran for prevention of stroke in AF patients

In a final draft guidance published on 1 November the UK National Institute for Health and Clinical Excellence (NICE) has recommended dabigatran (Pradaxa, Boehringer Ingelheim), in accordance with its licensed indications, for the prevention of stroke and systemic embolism in people with atrial fibrillation.
Cardiac Rhythm news for specialists

FDA approves rivaroxaban to prevent stroke in non-valvular atrial fibrillation patients

The Food and Drug Administration's approval is largely based on the results from the ROCKET-AF trial, a double-blind global phase III study that showed the safety and efficacy of rivaroxaban (Xarelto, Bayer Healthcare).
Cardiac Rhythm news for specialists

FDA’s Advisory Committee recommends approval of rivaroxaban

The US Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee recommended approval of rivaroxaban (Xarelto, Bayer) for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Cardiac Rhythm news for specialists

Novel anticoagulant apixaban reduces stroke and major bleeding compared with warfarin in AF patients

New data from the ARISTOTLE study showed that the rate of haemorrhagic stroke in the apixaban group was 49% lower and the rate of ischaemic stroke was 8% lower than in the warfarin group. Results were presented by Christopher Granger, USA, at the European Society of Cardiology (ESC) Congress (27-31 August 2011, Paris, France).
Cardiac Rhythm news for specialists

New renal impairment data from ROCKET AF study of rivaroxaban shows outcomes consistent with...

"The findings of this analysis demonstrate that rivaroxaban has the ability to prevent stroke in patients with moderate renal insufficiency, without elevating the risk of critical bleeding events such as intra-cranial haemorrhage," said Keith Fox at the European Society of Cardiology Congress in Paris.
Cardiac Rhythm news for specialists

Eliquis (apixaban) superior to warfarin for the reduction of stroke, major bleeding and mortality,...

Eliquis (Bristol-Myers Squibb and Pfizer), compared to standard of care warfarin, significantly reduced risk of stroke or systemic embolism by 21%, risk of major bleeding by 31% and mortality by 11%.
Cardiac Rhythm news for specialists

Pradaxa (dabigatran etexilate) now licensed for use in the UK

The recommended dose, Pradaxa 150mg twice daily, is licensed in the United Kingdom for the prevention of stroke and systemic embolism in eligible adult patients with atrial fibrillation.

ROCKET-AF results published

ROCKET-AF co-chair Keith Fox, from the Centre for Cardiovascular Science at the University of Edinburgh, UK, talks to Cardiac Rhythm News about the study and its implications.
Cardiac Rhythm news for specialists

Rivaroxaban superior than warfarin, ROCKET AF study shows

Rivaroxaban (Xarelto, Bayer) successfully met the primary efficacy endpoint of non-inferiority in the prevention of stroke and non-central nervous system embolism in non-valvular atrial fibrillation, with superior efficacy demonstrated compared to warfarin whilst on active treatment.
Cardiac Rhythm news for specialists

Double the number of deaths with dronedarone in permanent AF

The number of deaths in the dronedarone (Multaq, Sanofi Aventis) arm of the recently halted PALLAS study was double the number of deaths in the control arm, according to figures released by the US Food and Drug Administration (FDA).
Cardiac Rhythm news for specialists

Sanofi stops phase IIIb of trial using dronedarone in patients with permanent AF

The decision follows recommendations from the PALLAS trial's Operations Committee and the Data Monitoring Committee (DMC) which observed a significant increase in cardiovascular events in the dronedarone arm.
Cardiac Rhythm news for specialists

Eliquis (apixaban) meets primary and key secondary endpoints in phase III ARISTOTLE trial

In this study of patients with atrial fibrillation and at least one additional risk factor for stroke, Eliquis (Bristol-Myers and Pfizer) met the primary efficacy objective of non-inferiority to warfarin on the combined outcome of stroke.

Hein Heidbuchel

Hein Heidbuchel, director of Electrophysiology at the University Hospital Leuven, spoke to Cardiac Rhythm News about his career, influences and proudest moments. He also described the innovations that shaped his career, new technologies and EP education.
Cardiac Rhythm news for specialists

More ischaemic lesions with PVAC than with other techniques

The incidence of silent cerebral lesions after pulmonary vein isolation is different depending on the technology used, a new study has shown. Atrial fibrillation patients treated with multi-electrode PVAC showed higher incidence of silent cerebral ischaemic events compared to irrigated radiofrequency and cryoballoon ablation.
Cardiac Rhythm news for specialists

Dabigatran etexilate recommended for approval for stroke prevention in AF patients in Europe

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of dabigatran etexilate (Boehringer Ingelheim's Pradaxa) in the member states of the European Union for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation with one or more risk factors.
Cardiac Rhythm news for specialists

Apixaban reduces stroke by more than 50% in AF patients

In atrial fibrillation (AF) patients unsuitable for a vitamin K antagonist, apixaban reduces stroke by more than 50% compared to acetylsalicylic acid without a significant increase in major bleeding.
Cardiac Rhythm news for specialists

RE-LY sets benchmark for trials of thromboprophylaxis in AF

A total of 20,240 patients with non-valvular atrial fibrillation (AF) were assessed for eligibility in the RE-LY trial. Gregory Lip, University of Birmingham, UK, presented the results of the RE-LY sub-studies at the annual Europe AF meeting in London.
Cardiac Rhythm news for specialists

Boston Scientific to acquire Atritech

The Atritech Watchman left atrial appendage closure device is an alternative to warfarin for patients experiencing atrial fibrillation who are at high risk for stroke.
Cardiac Rhythm news for specialists

Application for rivaroxaban in AF patients submitted to the FDA

Clinical studies on rivaroxaban have shown no requirement for routine laboratory coagulation monitoring, and limited risk for food and drug interactions.
Cardiac Rhythm news for specialists

NICE guidance gives people living with AF more treatment options

Technology appraisal recommends the use of dronedarone in treating Atrial Fibrillation under specific conditions.
Cardiac Rhythm news for specialists

NICE publishes final draft guidance on dronedarone treating AF

Report suggests drug should only be considered as treatment option for people who have additional cardiovascular risks.
Cardiac Rhythm news for specialists

Multaq receives positive recommendation by NICE in new appraisal consultation document

The NICE appraisal committee's preliminary recommendation is to endorse Multaq as a first choice therapeutic option after beta-blockers for non-permanent AF patients.
Cardiac Rhythm news for specialists

Clopidogrel and dabigatran are alternatives to warfarin

Results of the ACTIVE A and RE-LY trials were presented by Stuart Connolly, McMaster University, Hamilton, Canada, at the Boston AF Symposium.

Lead management: Beyond see one, do one

Charles Love, The Ohio State University, analyses updates and highlights on issues related to lead management and extraction.
Cardiac Rhythm news for specialists

Watchman: Alternative to long-term warfarin therapy

An article published in The Lancet reports that patients with AF at risk of stroke could be offered percutaneous closure of the left atrial appendage instead of long-term warfarin therapy.
Cardiac Rhythm news for specialists

Edoxaban: Next generation oral anticoagulant under investigation

New treatment could offer further option in addition to current standard of care in thromboembolic disease in atrial fibrillation patients.
Cardiac Rhythm news for specialists

Final patient completes treatment in the RE-LY study

Trial compares dabigatran etexilate with warfarin for the prevention of stroke and non-CNS systemic embolism in patients with atrial fibrillation.
Cardiac Rhythm news for specialists

FDA’s committee recommends approval of dronedarone for AF

Efficacy of the new drug was assessed in the ATHENA trial, published in the 12 February 2009 issue of the New England Journal of Medicine.

Athena Poppas

Eric Prystowsky

Eric N Prystowsky

Pedro Brugada